ScreenerHero

NVCRNovoCure Ltd.

NAS · US · Healthcare · Medical Devices · novocure.com
17.10USDMkt Cap: 1.99B $P/E: —

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Fr…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$203.17BUSDP/E 37.7
SYK
Stryker Corporation
$126.37BUSDP/E 34.2
MDT
Medtronic plc
$119.49BUSDP/E 25.0
BSX
Boston Scientific Corporation
$73.00BUSDP/E 20.4
SHL
Siemens Healthineers AG
$48.43BUSDP/E 19.9
EW
Edwards Lifesciences Corporation
$51.70BUSDP/E 53.4
DXCM
DexCom, Inc.
$34.85BUSDP/E 36.5
GEHC
GE HealthCare Technologies Inc. Common Stock
$34.04BUSDP/E 17.2
PHIA
Koninklijke Philips N.V.
$25.08BUSDP/E 20.7
PHG
Koninklijke Philips N.V.
$26.80BUSDP/E 20.8
STE
STERIS plc
$23.20BUSDP/E 29.1
ZBH
Zimmer Biomet Holdings, Inc.
$19.26BUSDP/E 24.5
PEN
Penumbra, Inc.
$12.81BUSDP/E 79.7
SNN
Smith & Nephew plc
$12.25BUSDP/E 19.9
SN
Smith & Nephew plc
$11.48BUSDP/E 19.8
GMED
Globus Medical, Inc.
$11.67BUSDP/E 22.2
GKOS
Glaukos Corp
$10.91BUSD
EUZ
Eckert & Ziegler Strahlen-und Medizinte AG
$10.01BUSDP/E 17.1
PODD
Insulet Corporation
$10.28BUSDP/E 27.5
BIO
Bio-Rad Laboratories, Inc. Class A
$10.17BUSDP/E 46.3

Key Statistics

Company
Market Cap1.99B $
Enterprise Value1.91B $
Revenue (TTM)699.19M $
Gross Profit488.47M $
Net Income (TTM)-136.23M $
Revenue/Share6.157 USD
Last Price17.10 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.6K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISINJE00BYSS4X48
Valuation
P/E (Trailing)—
P/E (Forward)-21.77
PEG—
EV/EBITDA-14.02
EV/Revenue2.73
P/S2.96
P/B6.12
EPS (TTM)-1.27
EPS (Forward)-0.82
52W Range
17.0111% of range17.83
52W High17.83 USD
52W Low17.01 USD
Profitability
Gross Margin74.54%
Oper. Margin-5.75%
EBITDA Margin-19.51%
Profit Margin-20.79%
ROE-40.01%
ROA-16.94%
Growth
Revenue Growth15.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.03M $
CapEx (TTM)26.65M $
FCF Margin3.26%
FCF Yield1.14%
Net Debt-207.14M $
Net Debt/EBITDA1.52
Balance Sheet
Debt/Equity0.73
Current Ratio2.89
Quick Ratio2.66
Book Value/Sh2.904 USD
Cash/Share3.783 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)27.14 USD
Upside (mean)+58.7%
Target Range17.00 USD – 52.00 USD
$17.00+58.7% to mean$52.00
# Analysts7
Ownership
Shares Out.116.45M
Float96.42M
Insiders9.96%
Institutions90.69%
Short Interest
Short Ratio5.5d
Short % Float11.77%
Short % Out.8.71%
Shares Short10.14M
Short (prev mo.)11.88M
Technical
SMA 5016.45 (+4.0%)
SMA 20013.99 (+22.2%)
Beta0.98
S&P 52W Chg21.00%
Avg Vol (30d)939.44K
Avg Vol (10d)1.36M
Technical Indicators
RSI (14)51.6
MACD0.3430
MACD Signal0.2540
MACD Hist.+0.0890
BB Upper18.65 USD
BB Middle16.65 USD
BB Lower14.66 USD
BB Width23.93%
ATR (14)0.9469 USD
Vol Ratio (20d)0.62x